A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation (RESHAPE-HF)

November 5, 2018 updated by: Abbott Medical Devices
This trial is a randomized study of the MitraClip device in heart failure patients with clinically significant functional mitral regurgitation. A hierarchical composite of all-cause mortality and recurrent heart failure hospitalizations is hypothesized to occur at a lower rate with the use of the MitraClip device in addition to optimal standard medical therapy compared to optimal standard of care therapy alone.

Study Overview

Status

Terminated

Conditions

Intervention / Treatment

Detailed Description

This study is a clinical evaluation of the safety and effectiveness of the MitraClip System in the treatment of clinically significant functional mitral regurgitation in patients with chronic heart failure. The objective was to further study the safety and effectiveness of the MitraClip System for the treatment of clinically significant functional mitral regurgitation in New York Heart Association Functional Class III or IV chronic heart failure patients.

Due to lower than expected recruitment rate, Abbott Vascular sponsorship of the trial was terminated early.

Study Type

Interventional

Enrollment (Actual)

42

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Austria
    • Fadingerstraße 1
      • Linz, Fadingerstraße 1, Austria, A-4020
        • Allgemein öffentliches Krankenhaus Elisabethinen Linz
  • Belgium
      • Edegem, Belgium
        • UZA
  • Denmark
      • Aarhus, Denmark
        • Skejby Sykehus/Aarhus University Hospital
      • Copenhagen, Denmark
        • Rigshospitalet
      • Odense, Denmark
        • Odense Universitetshospital
  • Finland
      • Helsinki, Finland
        • Helsinki University Hospital
  • Germany
      • Aachen, Germany
        • Universitätsklinikum der RWTH - Aachen
      • Bad Krozingen, Germany
        • Herz-Zentrum
      • Berlin, Germany
        • Charité - Universitätsmedizin Berlin
      • Bernau, Germany
        • Evangelish-Freikirchliches Krankenhaus, Bernau
      • Göttingen, Germany
        • Herzzentrum Göttingen Universitätsmedizin, Göttingen
      • Hamburg, Germany
        • Asklepios Klinik St Georg, Hamburg
      • Hamburg, Germany
        • Kardiologische Gemeinschaftspraxis Mathey-Schofer, Hamburg
      • Hamburg, Germany
        • Universitäre Herzzentrum, Hamburg
      • Heidelberg, Germany
        • Uni-Klinikum Heidelberg
      • Mainz, Germany
        • Johannes Gütenberg University, Mainz
  • Italy
      • Brescia, Italy
        • Spedali Civili di Brescia
      • Catania, Italy
        • Ospedale Ferrarotto Alessi, Catania
      • Milano, Italy
        • Centro Cardiologico Monzino
      • Milano, Italy
        • Ospedale San Raffaele, Milano
      • Pisa, Italy
        • Azienda Ospedaliero Universitaria Pisana, Pisa
  • Netherlands
      • Amsterdam, Netherlands
        • Academisch Medisch Centrum
      • Leeuwarden, Netherlands
        • Medisch Centrum Leeuwarden
      • Nieuwegein, Netherlands
        • St Antonius Ziekenhuis, Nieuwegein
  • Spain
      • Barcelona, Spain
        • Hospital Sant Creu y Sant Pau,
  • Sweden
      • Stockholm, Sweden
        • Karolinska University Hospital, Stockholm
  • Switzerland
      • Basel, Switzerland
        • Universitatsspital Basel
      • Bern, Switzerland
        • Inselspital Bern
      • Zürich, Switzerland
        • Universitäts Spital Zürich

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Age between 18 years and 90 years old
  • Clinically significant functional mitral regurgitation (moderate-to-severe or severe mitral regurgitation), as defined by European Association of Echocardiography, within 90 days prior to randomization and confirmed by the Echocardiography Core Laboratory
  • Assessed by the investigator to be on optimal standard of care therapy for heart failure for at least 4 weeks with no dose changes of heart failure drugs (with the exception of diuretics) during the last 2 weeks immediately prior to randomization
  • Documented New York Heart Association Class III or Class IV heart failure, despite optimal standard of care therapy, within 90 days preceding randomization
  • Minimum of one documented hospitalization (acute care admission or emergency room visit) for heart failure within 12 months preceding randomization OR values of at least 350 pg/mL for BNP or at least 1400 pg/mL for NT-proBNP after optimal medical and/or device management within 90 days preceding randomization
  • Left ventricular ejection fraction (LVEF) ≥15% and ≤40% determined by transthoracic echocardiogram within 90 days prior to randomization and confirmed by the Echocardiography Core Laboratory
  • Left ventricular end diastolic diameter (LVEDD) ≥55 mm determined by transthoracic echocardiogram within 90 days prior to randomization and confirmed by the Echocardiography Core Laboratory
  • Patient is ambulatory and able to perform a 6MWT with the only limiting factor(s) being due to cardiovascular fitness
  • Subject agrees to return for all required post-procedure follow-up visits
  • The subject has been informed of the nature of the study and agrees to the study's provisions, including the possibility of randomization to the Control group, and has provided written informed consent as approved by the respective clinical site's Ethics Committee

Exclusion Criteria:

  • Mitral regurgitation is primarily due to degenerative disease of the mitral valve apparatus (Degenerative mitral regurgitation), as determined by transesophageal echocardiography
  • Status 1 heart transplant or prior orthotopic heart transplantation
  • Introduction of a new heart failure drug class within the last 4 weeks prior to randomization
  • Cardiovascular hospitalization within the last 2 weeks immediately prior to randomization
  • Evidence of acute coronary syndrome, transient ischemic attack or stroke within 90 days prior to randomization
  • Any percutaneous cardiovascular intervention, carotid surgery, cardiovascular surgery or atrial fibrillation ablation within 90 days prior to randomization
  • Implant of any rhythm management device (i.e., pacemaker, Cardiac Resynchronization Therapy with or without cardioverter-defibrillator (CRT or CRT-D), or Implantable Cardioverter Defibrillator (ICD) within 90 days prior to randomization, or revision of any implanted rhythm management device within 90 days prior to randomization
  • Need for any cardiovascular surgery
  • Mitral valve surgery is considered a therapeutic option for the subject
  • Renal replacement therapy
  • Uncontrolled hypertension (i.e., BP >180 mmHg systolic and/or >105 mmHg diastolic) or hypotension (i.e., BP <90 mmHg systolic)
  • Unstable angina pectoris as judged by the investigator, other clinically significant uncorrected valvular disease or left ventricular outflow obstruction, obstructive cardiomyopathy, poorly controlled fast atrial fibrillation or flutter, poorly controlled symptomatic brady- or tachyarrhythmias
  • 6MWT distance >450 meters
  • Mitral Valve Area (MVA) by planimetry <4.0 cm2; if MVA by planimetry is not measurable, pressure half-time measurement is acceptable; MVA must be confirmed by the Echocardiography Core Laboratory

  • Leaflet anatomy which may preclude MitraClip device implantation, proper device positioning on the leaflets, or sufficient reduction in mitral regurgitation that may include:

    • Evidence of calcification in the grasping area
    • Presence of significant cleft in the grasping area
    • Lack of both primary and secondary chordal support in the grasping area
    • Prior mitral valve surgery
    • Coaptation length ≤2 mm
    • Leaflet mobility length <1 cm
  • Presence of an IVC filter in the femoral vein that would interfere with the delivery catheter, or ipsilateral deep vein thrombosis (DVT) is present
  • Contraindication to transseptal catheterization
  • Subjects in whom transesophageal echocardiography is contraindicated
  • Echocardiographic evidence of intracardiac mass, thrombus, or vegetation
  • Active endocarditis or active rheumatic heart disease or leaflets degenerated from rheumatic disease (i.e., noncompliant, perforated)

  • Presence of any of the following:

    • Severe aortic stenosis (aortic valve area <1.0 cm2) or severe aortic regurgitation
    • Infiltrative cardiomyopathies (e.g., amyloidosis, hemochromatosis, sarcoidosis)
    • Hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, or any other structural heart disease causing heart failure other than dilated cardiomyopathy of either ischemic or non-ischemic etiology
    • Hemodynamic instability requiring inotropic support or mechanical heart circulatory support
  • Active infections requiring current antibiotic therapy
  • Known hypersensitivity or contraindication to procedural medications which cannot be adequately managed medically
  • Severe right ventricular failure or severe tricuspid regurgitation
  • History of bleeding diathesis or coagulopathy or subject who refuses blood transfusions
  • Pregnant or planning pregnancy within next 12 months. Note: Female patients of childbearing potential need to have a negative pregnancy test performed within 14 days prior to randomization and be adherent to an accepted method of contraception
  • Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the investigator
  • Currently participating in another therapeutic or interventional heart failure trial, or in any trial of an unapproved drug or device (Subjects participating in observational studies or registries may be considered as eligible)
  • Subject belongs to a vulnerable population per investigator's judgment or subject has any kind of disorder that compromises his/her ability to give written informed consent and/or to comply with study procedures

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: MitraClip Device
Subjects randomized to the Device group will undergo the MitraClip procedure in addition to optimal standard medical therapy.
Device: MitraClip
The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
No Intervention: Control
Subjects randomized to the Control group will receive optimal standard of care therapy alone.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hierarchical composite of all-cause mortality and recurrent heart failure hospitalizations
Time Frame: two years
The analysis will be carried out when the last patient completes 12-month follow-up. All follow-up, up to 24 months, will be included in the analysis.
two years

Secondary Outcome Measures

Outcome Measure
Time Frame
Composite of all-cause mortality, stroke, myocardial infarction, new need for renal replacement therapy, and non-elective cardiovascular surgery for device related complications in the Device group at 30 days
Time Frame: 30 days
30 days
Mitral regurgitation severity reduction to mild or mild-to-moderate at 12 months
Time Frame: 12 months
12 months
Change in Left Ventricular End Diastolic Volume (LVEDV) at 12 months over baseline
Time Frame: 12 months
12 months
Change in Left Ventricular End Systolic Volume (LVESV) at 12 months over baseline
Time Frame: 12 months
12 months
Change in 6 Minute Walk Test (6MWT) distance at 12 months over baseline
Time Frame: 12 months
12 months
Change in Quality of Life (QoL) score, as measured by Kansas City Cardiomyopathy Questionnaire (KCCQ), at 12 months over baseline
Time Frame: 12 months
12 months
New York Heart Association (NYHA) Functional Class I/II at 12 months
Time Frame: 12 months
12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Abbott Medical Devices

Investigators

  • Principal Investigator: Piotr Ponikowski, MD, PhD, Military Hospital, Medical University, Wroclaw, Poland

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2013

Primary Completion (Actual)

December 1, 2014

Study Completion (Actual)

January 1, 2015

Study Registration Dates

First Submitted

January 17, 2013

First Submitted That Met QC Criteria

January 17, 2013

First Posted (Estimate)

January 21, 2013

Study Record Updates

Last Update Posted (Actual)

November 7, 2018

Last Update Submitted That Met QC Criteria

November 5, 2018

Last Verified

November 1, 2018

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 12-513

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cardiovascular Diseases

Clinical Trials on MitraClip

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe